Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.

A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Abstract Text:

    jian ping xiongJian Ping Xiong,ling zhangLing Zhang,lu xing zhongLu Xing Zhong,feng qiuFeng Qiu,jun xuJun Xu,qing song taoQing Song Tao,xiao jun xiangXiao Jun Xiang,feng yuFeng Yu,xiao mei tangXiao Mei Tang,

    The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population. Fifty-one inpatients were enrolled to receive 85 mg/m oxaliplatin intravenously over a 2- h period on day 1, together with 400 mg/m2 leucovorin over 2- h, followed by a 46-h infusion of 5-fluorouracil at 2600 mg/m2 every 2 weeks. Treatment was given until progression or unmanageable toxicity ensued. In all, 51 patients received three or more oxaliplatin doses and a median of nine treatment cycles (range 3-16 cycles). Of the 51 eligible patients, two complete responses and 22 partial responses were observed for an overall response rate of 47.0% (95% confidence interval 35-64%). Median progression-free survival was 7.7 months (95% confidence interval 6.8-8.6) and median overall survival was 15.0 months (95% confidence interval 13.1-16.9). Toxicities were mild: five patients (9.8%) reported grade 3-4 neutropenia, 33 patients (64.8%) experienced grade 1-3 neurotoxicity and only six patients (11.8%) experienced grade 3 neurotoxicity. The leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX) regimen is active and well tolerated in patients with previously untreated advanced colorectal cancer in the Chinese population.

    A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Publishing Authors By Initials

    jp xiongJP Xiong,l zhangL Zhang,lx zhongLX Zhong,f qiuF Qiu,j xuJ Xu,qs taoQS Tao,xj xiangXJ Xiang,f yuF Yu,xm tangXM Tang,

    For similar organic chemicals: organometallic compounds: organoplatinum compounds research abstracts see: organic chemicals: organometallic compounds: organoplatinum compounds research

    PUBMED ID PMID:

    MEDLINE DATE:

    A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Anti-cancer drugs

    VOLUME: 18

    Page Numbers: 1103-7

    Journal Abbreviation: Anticancer Drugs

    ISSN: 0959-4973

    DAY: 30

    MONTH: Oct

    YEAR: 2007

    A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9100823

    A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Keywords Mesh Terms:

    KEYWORDS: Organoplatinum Compounds

    MESH TERMS: therapeutic use

    Chemical & Substance for Abstract: A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Information

    Substance Name: Leucovorin

    Registry Number: 58-05-9

    Grant and Affiliation Information for A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.

    AFFILIATION: Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, PRC. jpxiong@medmail.com.cn

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Anticancer Drugs

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News